Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy

BACKGROUND: Cetuximab, an anti-EGFR monoclonal antibody, is used to treat several cancers. However, many patients who initially respond to cetuximab acquire resistance. To examine mechanisms of acquired resistance, we developed a series of cetuximab-resistant (Ctx(R)) clones derived from the cetuxim...

Descripción completa

Detalles Bibliográficos
Autores principales: Iida, Mari, Brand, Toni M, Starr, Megan M, Huppert, Evan J, Luthar, Neha, Bahrar, Harsh, Coan, John P, Pearson, Hannah E, Salgia, Ravi, Wheeler, Deric L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283113/
https://www.ncbi.nlm.nih.gov/pubmed/25344208
http://dx.doi.org/10.1186/1476-4598-13-242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283113/
https://www.ncbi.nlm.nih.gov/pubmed/25344208
http://dx.doi.org/10.1186/1476-4598-13-242

Ejemplares similares